In recent years, the use of haploidentical donors for hematopoietic cell transplantation has expanded rapidly. Approximately 50% of patients requiring hematopoietic cell transplant lack a traditional donor. The use of HLA haploidentical-related donors is attractive due to nearly universal availability of this graft source. We summarize the current and future need for haploidentical donors and detail the rise of post-transplant cyclophosphamide as the dominant haploidentical approach. Further, we examine ongoing controversies in the field of haploidentical transplant, including conditioning regimens and graft source. Finally, we review the evidence available from preliminary comparative studies and discuss future direction of research.
INTRODUCTION
Hematopoietic cell transplantation (HCT) is the only curative option for many patients with malignant and non-malignant hematological disorders. At present, an HLA-matched sibling donor (MRD) is considered the gold standard for HCT. The availability of MRDs for patients requiring transplant is often cited as 30%. 1 However, a recent analysis shows that predicted MRD availability in the United States varies substantially by age and race. 2 Importantly, this analysis found that the current generation of younger adults (age 18-44) will be 1.5 times less likely to have a MRD available during peak transplant utilization. This decline is driven by falling total fertility rate, which was at a record low of 1.86 per woman in 2013. 3 This problem is even more striking in Japan and Europe, where the total fertility rate has hovered near to or below 1.5 for almost three decades.
Traditionally, the second-line donor for patients without a MRD is an HLA-matched unrelated donor (MUD). Unrelated donor search is expensive and time consuming. 4 Unfortunately, the odds of finding a matched donor vary significantly by race; Caucasians have a 75% 8/8 match probability, whereas the chances for patients of African descent are 16-19% . 5 An analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) found that 79% of non-Hispanic whites, compared with 13 and 8% of patients of Hispanic and African descent, respectively, found an 8/8 matched donor. 6 Consequently, white patients were nearly twice as likely to proceed to transplant. Although 7/8 or 6/8 matched donors can be found for most patients, large studies demonstrated that even one mismatched allele negatively impacts patient outcomes. 7, 8 In contrast, haploidentical donors are available for 495% of patients being evaluated for transplant. 9 These donors are easy to locate and highly motivated to undergo stem cell collection. 10 They are also generally available for repeat stem cell collection when necessary. 11 Consequently, they represent an important alternative to traditional donors.
EARLY CLINICAL TRIALS
Early studies examining haploidentical-related donors for haplo-HCT found limited success. The primary difficulties were high rates of engraftment failure and GvHD. [12] [13] [14] A large registry study found that engraftment failure occurred in 11% of patients receiving T-cell replete grafts from haploidentical donors, with acute and chronic GvHD occurring in 45% and 54%, respectively. 15 Given the poor outcomes associated with unmanipulated haplo-HCT, alternative strategies were sought. The first approaches circumvented these difficulties by T-cell depletion (TCD) and either positive or negative selection of CD34+ cells. 16, 17 These protocols successfully decreased GvHD, but led to slow immune reconstitution and high non-relapse mortality (NRM) from infections. 18 
DISCOVERY OF POST-TRANSPLANT CYCLOPHOSPHAMIDE
The capacity of cyclophosphamide (Cy) to attenuate immune response following allogeneic transplant was first observed by Berenbaum and Brown 19 in 1963. They utilized a mouse model to examine the effect of sc Cy on skin homograft transplants. They observed delayed rejection of the homograft when Cy was given at any time from day 0 to day +4. Further work in animal models demonstrated improved engraftment and decreased GvHD with post-transplant cyclophosphamide (PTCy) in the setting of allogeneic HCT. [20] [21] [22] [23] Later work in humans demonstrated that PTCy selectively depletes alloreactive naive CD4+ T cells while preserving the regulatory T cells. 24 The first study examining unmanipulated haplo-HCT with PTCy was conducted by O'Donnell et al. 25 All 13 patients underwent non-myeloablative (NMA) conditioning. They received 50 mg/kg of Cy on day +3 and began therapy with mycophenolate mofetil (MMF) and tacrolimus on day +4. Eighty percent (8/10) successfully engrafted with this regimen. Six developed acute GvHD (aGvHD) and one developed chronic GvHD (cGvHD). A two-center prospective trial of 68 patients was conducted utilizing a similar NMA protocol (Figure 1) . 26 One center administered a single dose 1 on day +3, whereas the other administered doses on days +3 and +4. Overall survival (OS), NRM and relapse at 1 year after transplant were 46, 15 and 51%. Graft failure occurred in 9 patients, with autologous recovery in 8. The rates of grade II-IV and grade III-IV acute graft versus host disease (aGvHD) were 34% and 6%, respectively. The proportion of patients developing extensive chronic graft versus host disease (cGvHD) was significantly lower in patients receiving two doses of PTCy (5% vs 25%, P = 0.04). Although the rate of relapse was high, the study proved the feasibility of the PTCy haplo-HCT protocol. Following this report, haplo-HCT with PTCy has become an area of intense research (Table 1 ). An early study compared TCD with PTCy directly. An analysis of two separate trials employing TCD haplo-HCT with positive CD34+ selection (n = 32) and T-cell replete (TCR) haplo-HCT with PTCy (n = 33) were resoundingly in favor of the PTCy protocol, with superior 1 year OS (64% vs 30%, P = 0.02) and NRM (16% vs 42%, P = 0.02). 27 Patients receiving the PTCy protocol also developed less cGvHD (7% vs 18%, P = 0.03). These results show PTCy-based protocols compare favorably with traditional TCD.
CONDITIONING REGIMENS
Given the relatively higher rates of relapse in the initial phase II study, an area of immediate interest was the use of more intense conditioning regimens with this protocol. 28 Solomon et al. with OS, NRM and relapse rate of 69, 10 and 40% at 1 year. They reported rates of 30% and 10% for grade II-IV and grade III-IV aGvHD, respectively. Severe cGvHD was only seen in 5% of patients at 18 months. Later, a study of 32 patients undergoing MA conditioning with Flu, melphalan and thiotepa (Thio) reported OS, NRM and relapse rate of 64, 16 and 34% at 1 year, with similar incidence of aGvHD and cGvHD. 27 A third MA approach, fractionated TBI and Flu, was studied in a phase II trial and yielded OS, NRM and relapse of 78, 3 and 24% at 2 years. 30 Other studies have examined similar approaches, including the use of Flu and Bu with Thio instead of Cy. [31] [32] [33] New results continue to be published, including updated data from the original two studies. 34, 35 However, choosing between these regimens continues to be a matter of clinical judgment due to lack of comparative trials.
GRAFT CELL SOURCE
Another area of interest has been the impact of graft cell source. At present, PBSC grafts are used in 485% of adult allogeneic HCTs. 36 Due to the anesthesia associated with a bone marrow (BM) harvest, peripherally mobilized hematopoietic cells are considered a better option by some providers. 37, 38 The use of PBSCs is also associated with higher CD34+ cell yields and faster immune reconstitution. [39] [40] [41] [42] [43] It does, however, deliver significantly more CD3+ cells, which are associated with higher rates of acute and chronic GvHD in other transplant settings. 37, [43] [44] [45] [46] Due to the concern about GvHD, the original Hopkins protocol used BM grafts. The vast majority of haploidentical transplants (82%) are performed with BM grafts. 47 Several centers, however, have investigated performing haplo-HCT with PBSCs. The first reports of this technique were published by Solomon et al. 29 as discussed above. While the use of PBSCs was initially associated with MA conditioning, multiple groups have shown that this approach is compatible with NMA conditioning. Raj et al. 48 published a retrospective multicenter study of 55 patients with a 2-year OS, NRM and relapse of 48%, 23% and 28%, respectively. They did, however, report a 61% incidence of grade II-IV aGvHD at 1 year. Several subsequent studies have reported similar results. 49, 50 The most extreme modification of the PTCy platform utilizing PBSCs is the 'two-step' approach pioneered by Grosso et al. 51 Their protocol requires the collection of unmobilized peripheral blood Abbreviations: aGvHD = acute GvHD; BM = bone marrow; cGvHD = chronic GvHD; MA = myeloablative; MDS = myelodysplastic syndrome; NMA = nonmyeloablative; NRM = non-relapse mortality; OS = overall survival; PBSC = peripheral blood stem cells; RIC = reduced intensity conditioning. RIC includes both RIC and NMA patients. Studies including 495% of grafts from either BM or PBSC were considered homogenous.
Development of haploidentical HCT with
Patients underwent MA conditioning and received the donor lymphocyte infusion on day − 6, followed by PTCy days − 3 and − 2, followed by a TCD graft. The initial trial showed similar results to other PTCy approaches, with OS, NRM and relapse at last follow up 54%, 22% and 32%, respectively. A follow-up study of patients in morphological remission at transplant demonstrated even better outcomes. 52 This approach represents an intriguing middle ground between the PTCy protocols and TCD techniques currently under study in Europe.
A study comparing PTCy haplo-HCT with BM vs PBSC grafts was published by Castagna et al. 53 They compared two groups of patients undergoing PTCy haplo-HCT after NMA conditioning with either BM (n = 46) or PBSC (n = 23) grafts. They found no significant difference in OS, NRM, relapse rate or GvHD between the two cohorts. Overall, multiple studies have shown the feasibility of either approach with a variety of conditioning regimens.
COMPARISON WITH CORD BLOOD
One of the earliest comparisons of interest was with patients undergoing umbilical cord blood transplant, as these patients also lack traditional donors. 54 Early studies found no difference between the two modalities. A study of 50 haplo-HCT and 50 double umbilical cord blood transplants found no statistically significant difference between the two modalities. 55 Another retrospective study of 92 haplo-HCT and 105 umbilical cord blood transplant patients also found no difference in outcomes between these two groups. 56 The largest study to date included 360 haplo-HCT and 558 umbilical cord blood transplant from a European registry. 57 It found slower neutrophil engraftment and a higher incidence of graft failure in the umbilical cord blood transplant group, but a lower incidence of cGvHD. No difference was seen in relapse, NRM and leukemia-free survival, despite a significantly higher proportion of patients in the haplo-HCT group with advanced disease and MA conditioning. A phase III open label randomized trial of umbilical cord blood transplant vs haploidentical transplant is ongoing and will provide further clarity in the comparison of these modalities (NCT01597778).
COMPARISON WITH MATCHED UNRELATED DONORS
At present, no study has shown a difference in OS between contemporaneously transplanted haplo-HCT and MUD patients. An early study by Raiola et al. 56 found no significant difference in outcomes in a heterogenous cohort. Di Stasi et al. 58 also found a longer time to neutrophil and platelet recovery in AML or myelodysplastic syndrome haplos vs MUDs, but no statistically significant difference in any other outcome. Gaballa et al. 59 found almost identical outcomes between patients undergoing 'two step' HCT with either haploidentical or MUD grafts.
The largest study in AML was published utilizing the CIBMTR registry and compared haplo-HCT patients (n = 192) with MUD patients (n = 1982). 47 Due to the large sample size, separate analyses were possible for MA and NMA regimens. In the MA cohort, relapse (44% vs 39%, P = 0.37), NRM (14% vs 20%, P = 0.14) and OS (45% vs 50%, P = 0.38) were not different between the haplo and MUD transplant at 3 years. However, aGvHD at 90 days (grade II-IV: 16% vs 33%, P o 0.0001, grade III-IV: 7% vs 13%, P = 0.02) and cGvHD at 3 years (30% vs 53%, P o 0.0001) were significantly lower in haplo-HCT, echoing previous finding. 30, 60 In the NMA cohort, a higher relapse rate (58% vs 42%, P = 0.0001) and a lower NRM (9% vs 23%, P = 0.002) was observed in haplo-HCT patients at 3 years. However, OS was not significantly different over the same time frame (46% vs 44%, P = 0.71). Similar to the MA cohort, aGvHD at 90 days and cGvHD at 3 years were significantly higher following MUD transplant.
Studies have also shown that haplo-HCT compares favorably with MUDs for lymphoma. An early report found lower relapse in haplo-HCT (n = 28) vs MUD (n = 24) in patients with relapsed or refractory Hodgkin lymphoma, raising the possibility of a significant graft-versus-lymphoma effect. 61 A CIBMTR study comparing a haplo-HCT cohort (n = 185) with a MUD HCT cohort with (n = 241) or without antithymocyte globulin (ATG) (n = 491) found that MUD patients were much more likely to experience grade III-IV aGvHD with ATG (relative ratio (RR) = 2.87, 95% confidence interval (CI), 1.52-5.4) or without ATG (RR = 2.45, 95% CI, 1.23-4.87) when compared with haplo-HCT patients. 62 Chronic GvHD rates were higher in ATG (RR = 3.64, 95% CI, 2.37-5.60) and non-ATG MUD (RR = 5.85, 95% CI, 3.96-8.64) when compared with haplo-HCT patients. However, the three groups were not statistically distinguishable in terms of OS, NRM and relapse.
The combined evidence of these studies indicates that haplo-HCT with PTCy is not inferior to MUD transplant. In fact, it may be associated with significant advantages in terms of both aGvHD and cGvHD. Randomized trials of donor source are needed to resolve lingering questions of efficacy. Other factors, including donor availability, time to transplant, cost and post-transplant quality of life, deserve continued attention.
COMPARISON WITH MATCHED RELATED DONORS
Four retrospective studies compared outcomes between haplo-HCT and MRD HCT. While patients undergoing haplo-HCT (n = 51) had lower rates of severe cGvHD (11% vs 4% at 2 years, P o0.05) than MRD patients (n = 50), their post-relapse survival at 12 months was significantly lower (67% vs 17%, P o 0.001). However, no differences in OS or relapse rate were noted. 60 Another study found haplo-HCT patients (n = 92) to be significantly less likely than MRD patients (n = 176) to experience grade II-IV aGvHD (14% vs 31%, P o0.001) without any difference in cGvHD or grade III-IV aGvHD. 56 No differences were seen in OS, relapse rate or NRM. Another study found longer time to neutrophil engraftment (18 vs 13 days, P o0.001) in haplo-HCT (n = 32) vs MRD (n = 87) patients with myelodysplastic syndrome or AML but no other difference in outcomes. 58 Interpretation of these studies is difficult due to the heterogeneity of the results and small sample sizes. A study in relapsed or refractory Hodgkin lymphoma showed lower NRM (hazard ratio = 0.35, 95% CI: 0.2-0.8) and relapse/progression (hazard ratio = 0.43, 95% CI: 0.2-0.9) in haplo-HCT patients (n = 28) compared with MRD patients (n = 38), but no statistical difference in aGvHD or cGvHD. 61 
OTHER HAPLOIDENTICAL TRANSPLANT PLATFORMS
The GIAC (G-CSF mobilization, intensified post-transplant immunosuppression, ATG and combination of PBSC and BM allografts) approach was developed at Peking University. 63 In the initial study of this protocol, all 171 patients successfully engrafted. 64 The 2-year probabilities of NRM, relapse and leukemia-free survival were 19.5%, 12.2% and 68.2% for standard risk patients and 31.1%, 38.9% and 42.1% for high risk patients, respectively. Further studies have continued to show promising results and the GIAC cohort is the largest group of haplo-HCT patients in the literature to date. 65 It is also the only haplo-HCT platform with a prospective comparative trial with MUDs. In the cohort of AML patients in first remission, the study found nearly identical OS, NRM and relapse, but higher GvHD and slower engraftment in the haplo-HCT cohort. 66 While the full GIAC protocol is presently only used in China, the groups in both Korea and Italy have shown the feasibility of haplo-HCT with G-CSF-mobilized PBSC grafts and ATG GvHD prophylaxis. 67, 68 Another haploidentical approach is the use of photodepletion to eliminate alloreactive T cells. Unmobilized pheresis product is incubated with TH9402 and irradiated recipient peripheral blood Development of haploidentical HCT with PTCy M Slade et al mononuclear cells. 69 Activated T cells become sensitive to fluorescent light, whereas Tregs are resistant to photodepletion. 70 Interestingly, pathogen-specific T cells are also relatively preserved. 71 These cells are then 'added back' following infusion of the TCD graft. In the initial study, all 19 patients achieved primary engraftment. Despite a higher rate of cGvHD, patients receiving higher T-cell doses had superior immune reconstitution, TRM and OS. 72 A phase II trial is ongoing and its results will allow more thorough evaluation of this technique. 73 Another strategy focuses on the direct depletion of TCRαβ-positive T cells, which are thought to be responsible for GvHD. These approaches preserve TCRγδ-positive T cells, which are involved in infectious immunity and the GvL effect. 74, 75 Early results in pediatric populations demonstrated acceptable rates of acute and chronic GvHD and 88% of patients achieved primary engraftment. 76 Trials in adults are ongoing, including the combination of αβ TCD and zoledronic acid, which has been shown to cause expansion of γδ T cells (NCT02508038).
FUTURE DIRECTIONS
A growing body of literature continues to examine haplo-HCT with PTCy. A recent paper validated the use of the Disease Risk Index in haplo-HCT with NMA conditioning. 77 Other studies have shown that this approach is feasible in older adults. 78, 79 Novel approaches to further reduce GvHD, such as the addition of upfront antithymocyte globulin, are currently under investigation. 80 Data on the impact of infectious agents continue to emerge, 81, 82 with CMV reactivation being a particular area of interest. 83, 84 At present, there is no evidence for increased infectious risk following haplo-HCT when compared with other transplant modalities.
Immune reconstitution following haplo-HCT is another area of significant interest. Several important studies have examined the effects of PTCy and the regeneration of T-cell subset following transplant. 24, 85, 86 Work is ongoing on other cellular subsets, including natural killer cells. 87 Relapse after transplant continues to be a challenge. Several promising approaches have emerged in recent years, including the use of early donor lymphocyte infusion. 88 Post-transplant natural killer cell infusion has also received significant attention, with early trials of several protocols ongoing. 89, 90 There is also interest in post-transplant consolidation with hypomethylating agents for AML and myelodysplastic syndrome. 91 Further comparative studies are also needed. The integration of PTCy into MUD and MRD transplant protocols is ongoing and comparison to haplo-HCT protocols would be illuminating. 92, 93 Data comparing GIAC and selective TCD platforms with PTCybased protocols is lacking. These questions need to be answered in the context of prospective clinical trials.
CONCLUSION
In summary, haplo-HCT with PTCy will continue to be an attractive transplant regimen based on the ready availability of donors and ease of administration. The need for alternate donors is likely to increase in the future. Current evidence suggests similar OS and possibly superior GvHD rate with haplo-HCT as compared with MUD or MRD transplantation. These conclusions are limited by the largely retrospective nature of the literature, and randomized studies are necessary for further evaluation. There continues to be interest in developing and advancing other haploidentical approaches. However, the relative ease, low cost and extensive experience with the PTCy approach continue to cement its place as the dominant haplo-HCT platform in most centers worldwide.
